$0.75
Bolt Biotherapeutics, a San Francisco-based company that develops immuno-oncology therapeutics, completed an upsized $220 million IPO, selling 11.5 million shares $20 each.
The stock opened at $26.10 on Friday and jumped more than 25% shortly after it opened for trading.
Our top picks for where to buy Bolt Biotherapeutics stock
How to buy Bolt Biotherapeutics Inc stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – BOLT. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Bolt Biotherapeutics Inc stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Bolt Biotherapeutics Inc stock price (NASDAQ: BOLT)
Use our graph to track the performance of BOLT stocks over time.Bolt Biotherapeutics Inc shares at a glance
Latest market close | $0.74 |
---|---|
52-week range | $0.71 - $1.56 |
50-day moving average | $0.80 |
200-day moving average | $1.02 |
Wall St. target price | $1.25 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-1.66 |
Is it a good time to buy Bolt Biotherapeutics Inc stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Bolt Biotherapeutics Inc price performance over time
Historical closes compared with the close of $0.736 from 2024-07-25
1 week (2024-07-19) | 0.68% |
---|---|
1 month (2024-06-27) | -1.55% |
3 months (2024-04-26) | -33.69% |
6 months (2024-01-26) | -31.21% |
1 year (2023-07-27) | -43.82% |
---|---|
2 years (2022-07-27) | -69.21% |
3 years (2021-07-27) | 11.78 |
5 years (2019-07-23) | N/A |
Bolt Biotherapeutics Inc financials
Revenue TTM | $11.3 million |
---|---|
Gross profit TTM | $1.6 million |
Return on assets TTM | -26.81% |
Return on equity TTM | -48.14% |
Profit margin | 0% |
Book value | $2.73 |
Market Capitalization | $27.9 million |
TTM: trailing 12 months
Bolt Biotherapeutics Inc share dividends
We're not expecting Bolt Biotherapeutics Inc to pay a dividend over the next 12 months.
Bolt Biotherapeutics Inc share price volatility
Over the last 12 months, Bolt Biotherapeutics Inc's shares have ranged in value from as little as $0.71 up to $1.56. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bolt Biotherapeutics Inc's is 0.934. This would suggest that Bolt Biotherapeutics Inc's shares are less volatile than average (for this exchange).
To put Bolt Biotherapeutics Inc's beta into context you can compare it against those of similar companies.
- Seagen (SGEN.US): 0.321
- MacroGenics (MGNX.US): 2.074
- Merus BV (MRUS.US): 1.123
Bolt Biotherapeutics Inc overview
Bolt Biotherapeutics, Inc. , a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc. , Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University.
Frequently asked questions
nullWhat percentage of Bolt Biotherapeutics Inc is owned by insiders or institutions?
Currently 3.469% of Bolt Biotherapeutics Inc shares are held by insiders and 64.277% by institutions. How many people work for Bolt Biotherapeutics Inc?
Latest data suggests 100 work at Bolt Biotherapeutics Inc. When does the fiscal year end for Bolt Biotherapeutics Inc?
Bolt Biotherapeutics Inc's fiscal year ends in December. Where is Bolt Biotherapeutics Inc based?
Bolt Biotherapeutics Inc's address is: 900 Chesapeake Drive, Redwood City, CA, United States, 94063 What is Bolt Biotherapeutics Inc's ISIN number?
Bolt Biotherapeutics Inc's international securities identification number is: US0977021049
More guides on Finder
-
How to invest in ARK Venture Fund (ARKVX)
Learn how to invest in Cathie Wood’s ARK Venture Fund in 5 easy steps.
-
Best brokerage accounts for index funds [July 2024]
Our picks of the best brokerage accounts for index funds for beginners, teens, proprietary funds and more.
-
Options trading strategies for beginners
Learn these options trading strategies to lock in profits and get acquainted with a new asset class.
-
Opto review 2024: $0 commission, fractional theme investing
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
-
How to buy the new spot Ethereum ETFs
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
-
Best broker cash sweep rates for July 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 top semiconductor stocks to buy in 2024
We’ve rounded up stats on some of the most popular semiconductor stocks, along with information on how they compare and how to invest.
-
11 best brokerage accounts of July 2024: Top picks for investors
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
Ask a question